Latest News & Events
Learn more about the latest Delphi Diagnostics news and the Endocrine Activity Index (EAI) Test by reading the press releases below. EAI is known in publications as the Sensitivity to Endocrine Therapy (SET2,3) Test. Clicking on the links below will take you to the full text news pages.
Latest News
Houston, TX, February 16, 2026 — New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) identifies postmenopausal women with hormone receptor–positive (HR+), HER2-negative breast cancer who may derive meaningful benefit from extended endocrine therapy. The findings were presented by Eleftherios P. Mamounas, MD, AdventHealth Cancer Institute, Orlando, FL, in a general session on behalf of the NRG Oncology/NSABP investigators, under the title: “Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial.”
All News
February 10, 2025
Data Presented at SABCS 2025 Reinforce the Endocrine Activity Index® (EAI®) as a Powerful Tool to Inform Treatment Decisions in HR+/HER2- Breast Cancer
December, 2025
Delphi Diagnostics Co-Founder and Lead Inventor W. Fraser Symmans Honored with a Brinker Award by the Susan G. Komen® Foundation
November 4, 2025
Delphi Diagnostics® Announces Four Abstracts and One General Session Presentation Featuring the Endocrine Activity Index® to be Presented at the San Antonio Breast Cancer Symposium
March 5, 2025
New Data Confirms Endocrine Activity Index® as a Predictor of Benefit from Dose-Dense Chemotherapy
August 5, 2024
Two Abstracts Highlighting the Endocrine Activity Index were Presented at the 2024 Annual Society of Clinical Oncology Meeting
April 2, 2023
Delphi Diagnostics® Inc. Announces a Strategic Partnership with Protean BioDiagostics to Offer the Endocrine Activity Index
March 9, 2023
Delphi Diagnostics™ Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX®) in Node-Positive Breast Cancer
October 27, 2022
Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
September 22, 2022
Delphi Diagnostics™ Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
June 13, 2022
SET2,3 Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
December 14, 2021
SET2,3 index adds independent, complementary information to personalize breast cancer treatment
Latest Events
ASCO - Annual Meeting
American Society of Clinical Oncology (ASCO)
Chicago, IL
May 29 – June 2, 2026
Contact Us
Want to learn more about the Endocrine Activity Index (EAI) or Delphi Diagnostics?
